Damora Therapeutics, Inc.

DMRA Nasdaq SEC CIK 1800315
Follow Damora Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$32M −921.1% vs same quarter last year
EPS, diluted −$0.40 +83.1% vs same quarter last year
Operating cash flow −$17.2M −558.8% vs same quarter last year
Operating income −$36.9M −1068% vs same quarter last year
Net income by quarter
−$6.7M
−$2.5M
−$3.4M
−$3.1M
−$200.7M
−$27.8M
−$31.2M
−$32M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
−$80M−$60M−$40M−$20M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25-
FY24−$21.4M
FY23−$38.3M
FY22−$61.6M
FY21−$51.8M
FY20−$34.8M
FY19−$36.5M
FY18-